|
Dr. Burgess is a clinical and translational investigator in sarcoma, with active involvement in current clinical trials. Dr. Burgess’ research efforts include collaboration with Dr. Lisa Butterfield, director of the Immune Monitoring and Cellular Products Laboratory (IMCPL) at the University of Pittsburgh Cancer Institute (UPCI), with a focus on analyzing peripheral blood samples from SARC 028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas. Planned analyses include the assessment of T-cell populations and other immune markers in the circulation with correlation to tumor response to pembrolizumab. Results will be combined with the other correlative studies from SARC 028 including correlation of response with PD-L1 status and immune monitoring within the tumor. These transitional studies should offer unique insights into the biology of PD-1 blockade in sarcoma. Dr. Burgess serves as local principal investigator (PI) for SARC 028, a clinical trial through Sarcoma Alliance for Research through Collaboration (SARC), in which the University of Pittsburgh is a SARC-participating institution.
|